Alberto Carretero-González
University of California, San Francisco(US)UCSF Helen Diller Family Comprehensive Cancer Center(US)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Peptidase Inhibition and Analysis, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment
Most-Cited Works
- → Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials(2018)94 cited
- → The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials(2020)72 cited
- → Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future(2021)52 cited
- → Exosomes: Definition, Role in Tumor Development and Clinical Implications(2018)40 cited
- → Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials(2022)34 cited
- → Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis(2022)25 cited
- → Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti–PD-1/PD-L1 Therapy(2020)21 cited
- → Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials(2019)17 cited
- → Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.(2021)13 cited
- → Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer(2023)11 cited